Our Impact
Summer 2016 Issue of Compass Now Available
The Summer 2016 issue of Compass is now available online. As part of our most recent round of funding, we’ve announced $704,000 in funding for […]
Read More ›We’re Partnering With The Mighty!
We’re thrilled to announce a new partnership that will bring Cure SMA’s resources in front of The Mighty‘s wide-reaching readership. We will now have a […]
Read More ›Cure SMA Plans a Series of Educational Modules for the SMA Community
With the recent news that Biogen and Ionis will submit nusinersen for FDA approval—along with other recent developments, including the breakthrough designation for AveXis’s gene […]
Read More ›Important Milestone Reached with First New Drug Program for SMA Advancing Towards Approval with the FDA
Biogen and Ionis have been testing nusinersen in clinical trials and today announced that they will close ENDEAR, the Phase 3 trial testing nusinersen in […]
Read More ›Cure SMA Announces $2.5 Million in New Planned Research Funding
At the 2016 Annual SMA Conference, Cure SMA announced $2.5 million in new planned research funding over the next 12 months. This funding will be […]
Read More ›Cure SMA Posts Keynote Presentations on the NDA Process
The ultimate goal in drug development is to get treatments approved for as many people as possible, as quickly as possible. Because these issues are […]
Read More ›Cure SMA Funds $2 Million in New Research in 2015-2016
Over the past few months, Cure SMA has announced a total of just over $2 million in new research funding. Our model is designed to […]
Read More ›The 2016 Annual SMA Conference is Here!
The 2016 Annual SMA Conference, now in its 28th year, is set to kick off on June 16 and continue into a weekend full of […]
Read More ›Cure SMA Receives 2016 NIH Grant
For the eighth consecutive year, Cure SMA has received a grant from the National Institutes of Health (NIH) for the SMA Researcher Meeting. This year’s […]
Read More ›Cure SMA Releases June 2016 Update to the SMA Drug Pipeline
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 18 active programs. 14 pharmaceutical partners. 6 programs in clinical trials. […]
Read More ›